LINACLOTIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LINACLOTIDE (LINACLOTIDE).
Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (cGMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.
| Metabolism | Minimally metabolized; primarily degraded by intestinal peptidases. Not a substrate for CYP450 enzymes. |
| Excretion | Primarily fecal as intact peptide (95%); renal excretion of absorbed drug is minimal (<5%). |
| Half-life | Approximately 9–10 hours (terminal half-life in plasma), supporting once-daily dosing. |
| Protein binding | Approximately 94% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | ~5.2 L/kg (large Vd indicating extensive tissue distribution). |
| Bioavailability | Oral: ~0.1% (extremely low due to extensive degradation in GI tract and first-pass metabolism). |
| Onset of Action | Oral: 1–2 hours after first dose (increase in spontaneous bowel movements noted). |
| Duration of Action | Approximately 24 hours; clinical effect correlates with once-daily dosing regimen. |
145 mcg orally once daily, at least 30 minutes before the first meal of the day.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for any degree of renal impairment, including end-stage renal disease on dialysis. |
| Liver impairment | No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; caution advised due to potential increased sensitivity or gastrointestinal effects, but no pharmacokinetic differences observed in elderly vs younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LINACLOTIDE (LINACLOTIDE).
| Breastfeeding | Linaclotide is minimally absorbed systemically; its active metabolite is not measurable in plasma. No data on presence in human milk. M/P ratio unknown; likely low risk due to poor oral bioavailability and large molecular size. |
| Teratogenic Risk | Linaclotide is not systemically absorbed after oral administration; animal studies at high oral doses showed no teratogenicity. No human data available; risk to fetus is likely low due to negligible systemic exposure. |
| Fetal Monitoring |
■ FDA Black Box Warning
No boxed warning.
| Serious Effects |
["Known or suspected mechanical gastrointestinal obstruction.","History of a serious hypersensitivity reaction to linaclotide or any component of the formulation."]
| Precautions | ["Not recommended in pediatric patients; avoid use in patients with known or suspected mechanical gastrointestinal obstruction.","May cause diarrhea, which can be severe; instruct patients to discontinue if severe diarrhea occurs.","Use caution in patients with inflammatory bowel disease (Crohn's, ulcerative colitis) or a history of colonic obstruction."] |
Loading safety data…
| No specific monitoring required; standard obstetrical care applies. |
| Fertility Effects | Based on animal studies, no effects on fertility were observed at clinically relevant exposures. |